Diatrizoate Sodium
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00271 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | osteoarthritis susceptibility | KG + DL |
| 2 | rheumatoid arthritis | KG + DL |
| 3 | osteoarthritis | KG + DL |
| 4 | hemoglobinopathy | KG + DL |
| 5 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 6 | brachyolmia | KG + DL |
| 7 | acromesomelic dysplasia, Hunter-Thompson type | KG + DL |
| 8 | brachyolmia-amelogenesis imperfecta syndrome | KG + DL |
| 9 | myosclerosis | KG + DL |
| 10 | brachydactyly-syndactyly syndrome | KG + DL |
| 11 | pseudoachondroplasia | KG + DL |
| 12 | alopecia | KG + DL |
| 13 | arthropathy | KG + DL |
| 14 | beta-thalassemia with other manifestations | KG + DL |
| 15 | partial deletion of the short arm of chromosome 16 | KG + DL |
| 16 | congestive heart failure | KG + DL |
| 17 | congenital hypotrichosis milia | KG + DL |
| 18 | hemolytic anemia due to glucophosphate isomerase deficiency | KG + DL |
| 19 | pyruvate kinase deficiency of red cells | KG + DL |
| 20 | hypotrichosis simplex of the scalp | KG + DL |
| 21 | pyropoikilocytosis, hereditary | KG + DL |
| 22 | diffuse alopecia areata | KG + DL |
| 23 | female breast carcinoma | KG + DL |
| 24 | acute pulmonary heart disease | KG + DL |
| 25 | gout | KG + DL |
| 26 | peripheral vascular disease | KG + DL |
| 27 | hepatic porphyria | KG + DL |
| 28 | toxocariasis | KG + DL |
| 29 | chronic pulmonary heart disease | KG + DL |
| 30 | hypertensive disorder | KG + DL |
| 31 | myocardial infarction | KG + DL |
| 32 | primitive portal vein thrombosis | KG + DL |
| 33 | hepatoportal sclerosis | KG + DL |
| 34 | hepatopulmonary syndrome | KG + DL |
| 35 | early-onset familial noncirrhotic portal hypertension | KG + DL |
| 36 | idiopathic copper-associated cirrhosis | KG + DL |
| 37 | pulmonary hypertension owing to lung disease and/or hypoxia | KG + DL |
| 38 | pulmonary hypertension with unclear multifactorial mechanism | KG + DL |
| 39 | pulmonary hypertension | KG + DL |
| 40 | antithrombin deficiency type 2 | KG + DL |
| 41 | headache disorder | KG + DL |
| 42 | peripheral arterial disease | KG + DL |
| 43 | malignant hypertensive renal disease | KG + DL |
| 44 | malignant renovascular hypertension | KG + DL |
| 45 | benign prostatic hyperplasia (disease) | KG + DL |
| 46 | intermittent vascular claudication | KG + DL |
| 47 | factor 5 excess with spontaneous thrombosis | KG + DL |
| 48 | migraine disorder | KG + DL |
| 49 | Braddock syndrome | KG + DL |
| 50 | heparin cofactor 2 deficiency | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.